BioSpace News Archive

Izoview, 5th generation, enhanced product design for performance improvements, added usability, increasing competitive advantages and target market.

Medline’s behind-the-scenes support helps Spectrum Health enhance operational, financial and clinical efficiencies across the system

Strongbridge Biopharma plc, (Nasdaq: SBBP), today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,020,393 entitled, “Methods of Treating Disease with Levoketoconazole”

Timber Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced that on June 3, 2021 its 2021 Annual Meeting of Stockholders was convened without a quorum.

First patient dosed by Vincerx marks significant milestone in Company’s development

Resonant Inc. announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021, as well as the Lytham Partners Summer Investor Conference taking place virtually June 14-16, 2021, and the East Coast IDEAS Investor Conference, taking place virtually June 16-17.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring system – the Eversense® CGM System – announced the results of the PROMISE Study evaluating the accuracy and safety of the next generation Eversense CGM System for up to 180 days with reduced calibrations.

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today presented clinical data from its Phase 3 PEDFIC 1 study and an interim data cut of the PEDFIC 2 long-term extension study of its lead product candidate, Bylvay (odevixibat)

Neovasc Inc. is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on June 3, 2021 in Vancouver, B.C..